Published in Cancer Immun on June 05, 2009
Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. Immunity (2013) 3.38
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Strategies for cancer vaccine development. J Biomed Biotechnol (2010) 1.26
Trial watch: DNA vaccines for cancer therapy. Oncoimmunology (2013) 1.11
CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother (2011) 1.10
Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clin Cancer Res (2010) 0.90
Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin Immunol (2010) 0.87
DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother (2014) 0.87
Preclinical and clinical development of DNA vaccines for prostate cancer. Urol Oncol (2013) 0.86
Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Oncoimmunology (2012) 0.83
Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402. J Transl Med (2010) 0.83
Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review). Oncol Rep (2014) 0.82
Emerging cancer vaccines: the promise of genetic vectors. Cancers (Basel) (2011) 0.81
Insights into the Role of PAX-3 in the Development of Melanocytes and Melanoma. Open Cancer J (2011) 0.81
DNA vaccination: using the patient's immune system to overcome cancer. Clin Dev Immunol (2010) 0.80
Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. J Immunother Cancer (2013) 0.77
Harnessing DNA-induced immune responses for improving cancer vaccines. Hum Vaccin Immunother (2012) 0.77
Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma. BMC Vet Res (2015) 0.76
The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. Int J Mol Sci (2017) 0.75
Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma. BMC Vet Res (2015) 0.75
State of the art in tumor antigen and biomarker discovery. Cancers (Basel) (2011) 0.75
Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination. J Immunother Cancer (2013) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 17.54
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A (1996) 5.26
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 5.22
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science (1996) 3.82
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol (1999) 3.49
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol (2008) 2.59
Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol (2007) 2.59
Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med (1999) 2.15
Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest (1998) 2.02
Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res (1996) 1.99
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc Natl Acad Sci U S A (1980) 1.86
Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol (1999) 1.67
Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine (2005) 1.59
Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother (1997) 1.47
Immune selection after antigen-specific immunotherapy of melanoma. Surgery (1999) 1.34
Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J Invest Dermatol (1988) 1.34
Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther (2008) 1.22
Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther (2007) 1.18
The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist (2008) 1.17
Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery (2000) 1.15
Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin Cancer Res (2005) 1.14
T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res (2002) 1.12
Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol (1997) 1.11
Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun (2006) 1.04
In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring. Cytotherapy (2006) 1.01
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). Oncologist (2008) 1.00
Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells. Gene Ther (2003) 0.82
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature (2003) 14.49
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 11.14
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46
The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med (2013) 8.76
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
The cancer/testis genes: review, standardization, and commentary. Cancer Immun (2004) 4.78
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 4.77
Comparing genomic expression patterns across species identifies shared transcriptional profile in aging. Nat Genet (2004) 4.77
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev (2002) 4.63
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol (2004) 4.06
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst (2007) 3.60
Evolution of alternative transcriptional circuits with identical logic. Nature (2006) 3.58
The evolution of combinatorial gene regulation in fungi. PLoS Biol (2008) 3.53
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev (2002) 3.28
Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genet (2007) 3.24
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 3.12
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev (2007) 2.96
Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice. J Cell Biol (2007) 2.94
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol (2007) 2.83
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A (2004) 2.80
Evolutionary dynamics of cancer in response to targeted combination therapy. Elife (2013) 2.76
pSAT vectors: a modular series of plasmids for autofluorescent protein tagging and expression of multiple genes in plants. Plant Mol Biol (2005) 2.75
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res (2003) 2.73
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res (2005) 2.73
Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol (2008) 2.68
Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A (2008) 2.66
Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res (2003) 2.62
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A (2007) 2.61
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res (2003) 2.53
NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res (2006) 2.44
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res (2010) 2.31
Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med (2003) 2.30
The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys (2012) 2.29
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol (2008) 2.28
Subcellular localization of interacting proteins by bimolecular fluorescence complementation in planta. J Mol Biol (2006) 2.26
Evolution of eukaryotic transcription circuits. Science (2008) 2.24
Immune modulation in cancer with antibodies. Annu Rev Med (2013) 2.23
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res (2011) 2.20
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A (2007) 2.19
Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med (2012) 2.19
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A (2006) 2.19
Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J Clin Oncol (2003) 2.18
Dynamic XML-based exchange of relational data: application to the Human Brain Project. AMIA Annu Symp Proc (2003) 2.16